Prospective study of trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' health study

Journal of the National Cancer Institute

Volumn 101, Issue 20, 2009, Pages 1406-1411

  Stark, Jennifer R ^a,b   Judson, Gregory ^a   Alderete, John F ^d   Mundodi, Vasanthakrishna ^d   Kucknoor, Ashwini S ^d   Giovannucci, Edward L ^a,b   Platz, Elizabeth A ^e   Sutcliffe, Siobhan ^f   Fall, Katja ^a,g   Kurth, Tobias ^a,c,h   Ma, Jing ^b   Stampfer, Meir J ^a,b   Mucci, Lorelei A ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CHANNING LABORATORY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f MO   (United States)

^g KAROLINSKA INSTITUTE   (Sweden)

^h INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SEROPREVALENCE; TRICHOMONIASIS;

AGED; ANIMALS; ANTIBODIES, PROTOZOAN; BONE NEOPLASMS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHYSICIANS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RESEARCH DESIGN; TRICHOMONAS INFECTIONS; TRICHOMONAS VAGINALIS;

EID: 70350514580     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp306     Document Type: Article

References (30)

1. De Marzo AM, Platz EA, Sutcliffe S, et al. Infl ammation in prostate car-cinogenesis. Nat Rev Cancer. 2007 ; 7 ( 4 ): 256-269.
2. World Health Organization. Global Prevalence and Incidence of Selected Curable Transmitted Infections.Geneva, Switzerland: World Health Organization ; 2001.
3. Miller WC, Swygard H, Hobbs MM, et al. The prevalence of trichomo-niasis in young adults in the United States. Sex Transm Dis. 2005 ; 32 ( 10 ): 593-598.
4. Kuberski T. Evaluation of the indirect hemagglutination technique for study of Trichomonas vaginalis infections, particularly in men. Sex Transm Dis. 1978 ; 5 ( 3 ): 97-102.
5. Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis. 2007 ; 44 ( 1 ): 13-22.
6. Krieger JN, Jenny C, Verdon M, et al. Clinical manifestations of trichomoniasis in men. Ann Intern Med. 1993 ; 118 ( 11 ): 844-849.
7. Krieger JN, Verdon M, Siegel N, Holmes KK. Natural history of urogeni-tal trichomoniasis in men. J Urol. 1993 ; 149 ( 6 ): 1455-1458.
8. Weston TET, Nichol CS. Natural history of trichomonal infection in males. Br J Vener Dis. 1963 ; 39 ( 4 ): 251-257.
9. Krieger JN. Trichomoniasis in men: old issues and new data. Sex Transm Dis. 1995 ; 22 ( 2 ): 83-96.
10. Gardner WA, Culberson DE, Bennett BD. Trichomonas vaginalis in the prostate gland. Arch Pathol Lab Med. 1986 ; 110 ( 5 ): 430-432.
11. van Laarhoven PH. Trichomonas vaginalis, a pathogen of prostatitis. Arch Chir Neerl. 1967 ; 19 ( 3 ): 263-273.
12. Sutcliffe S, Giovannucci E, Alderete JF, et al. Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006 ; 15 ( 5 ): 939-945.
13. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996 ; 334 ( 18 ): 1145-1149.
14. Final report on the aspirin component of the ongoing Physicians ' Health Study Steering Committee of the Physicians ' Health Study Research Group. N Engl J Med. 1989 ; 321 ( 3 ): 129-135.
15. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996 ; 88 ( 16 ): 1118-1126.
16. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005 ; 97 ( 17 ): 1248-1253.
17. Smith EB, Frierson HF Jr, Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer. 2002 ; 94 ( 8 ): 2282-2287.
18. Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009 ; 27 ( 21 ): 3459-3464.
19. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006 ; 6 ( 1 ): 24-37.
20. Sutcliffe S, Alderete JF, Till C, et al. Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int J Cancer. 2009 ; 124 ( 9 ): 2082-2087.
21. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006 ; 98 ( 8 ): 529-534. (Pubitemid 43898816)
22. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007 ; 121 ( 7 ): 1571-1578. (Pubitemid 47328718)
23. Addis MF, Rappelli P, Delogu G, Carta F, Cappuccinelli P, Fiori PL. Cloning and molecular characterization of a cDNA clone coding for Trichomonas vaginalis alpha-actinin and intracellular localization of the protein. Infect Immun. 1998 ; 66 ( 10 ): 4924-4931.
24. Addis MF, Rappelli P, Pinto De Andrade AM, et al. Identifi cation of Trichomonas vaginalis alpha-actinin as the most common immunogen recognized by sera of women exposed to the parasite. J Infect Dis. 1999 ; 180 ( 5 ): 1727-1730.
25. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2006. Atlanta, GA: U.S. Department of Health and Human Services ; 2007.
26. Sutcliffe S, Giovannucci E, Gaydos CA, et al. Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2007 ; 16 ( 8 ): 1573-1580.
27. Sutcliffe S, Giovannucci E, De Marzo AM, Leitzmann MF, Willett WC, Platz EA. Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006 ; 15 ( 11 ): 2160-2166.
28. Korodi Z, Dillner J, Jellum E, et al. Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev. 2005 ; 14 ( 12 ): 2952-2955.
29. Korodi Z, Wang X, Tedeschi R, Knekt P, Dillner J. No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case-control study. J Infect Dis. 2005 ; 191 ( 12 ): 2008-2011.
30. Anttila T, Tenkanen L, Lumme S, et al. Chlamydial antibodies and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 ; 14 ( 2 ): 385-389.